Optimizing adjuvant endocrine therapy for postmenopausal breast cancer: the modified CYP2D6 genotype-based modeling analyses

被引：0
|
作者：
Di, G. H. [1 ]
Shao, Z. M. [1 ]
Yu, K. D. [1 ]
机构：
[1] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70445-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [41] CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
    He, Wei
    Grassmann, Felix
    Eriksson, Mikael
    Eliasson, Erik
    Margolin, Sara
    Thoren, Linda
    Hall, Per
    Czene, Kamila
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 548 - +
  • [42] RELATIONSHIP OF CYP2D6 (DEBRISOQUINE HYDROXYLASE) GENOTYPE TO BREAST-CANCER SUSCEPTIBILITY
    BUCHERT, ET
    WOOSLEY, RL
    SWAIN, SM
    OLIVER, SJ
    COUGHLIN, SS
    PICKLE, L
    TROCK, B
    RIEGEL, AT
    PHARMACOGENETICS, 1993, 3 (06): : 322 - 327
  • [43] CYP2D6 genotype and the incidence of anal and vulvar cancer
    Chen, C
    Cook, LS
    Li, XY
    Hallagan, S
    Madeleine, MM
    Daling, JR
    Weiss, NS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1999, 8 (04) : 317 - 321
  • [44] Clinical outcomes in early breast cancer patients on adjuvant tamoxifen: Impact of CYP2D6 genotype and observed endoxifen concentrations
    Panuganty, Veera Durga Sravanthi
    Keller, Denise
    Teft, Wendy A.
    Lenehan, John Gordon
    Potvin, Kylea Raijann
    Younus, Jawaid
    Vandenberg, Theodorus Anthony
    Logan, Diane Mary
    Hahn, Karin
    Brackstone, Muriel
    Blanchette, Phillip Stanley
    Perera, Francisco
    Choi, Yun-Hee
    Kim, Richard Brian
    CANCER RESEARCH, 2020, 80 (04)
  • [45] CYP2D6*4-genotype influences tamoxifen efficacy in advanced breast cancer
    Regierer, A. C.
    Karle, J.
    Bolbrinker, J.
    Vogl, S.
    Kreutz, R.
    Denkert, C.
    Eucker, J.
    Wischnewsky, M.
    Possinger, K.
    ONKOLOGIE, 2012, 35 : 109 - 109
  • [46] Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
    Damodaran, Solai Elango
    Pradhan, Suresh Chandra
    Umamaheswaran, Gurusamy
    Kadambari, Dharanipragada
    Reddy, K. Sathyanarayana
    Adithan, Chandrasekaran
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 75 - 81
  • [47] The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
    Al-khalil, Wouroud Ismail
    Al-Salhi, Lana
    Rijjal, Sara
    Aljamali, Majd
    Youssef, Lama A.
    BMC CANCER, 2022, 22 (01)
  • [48] The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
    Wouroud Ismail Al-khalil
    Lana Al-Salhi
    Sara Rijjal
    Majd Aljamali
    Lama A. Youssef
    BMC Cancer, 22
  • [49] Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
    Solai Elango Damodaran
    Suresh Chandra Pradhan
    Gurusamy Umamaheswaran
    Dharanipragada Kadambari
    K. Sathyanarayana Reddy
    Chandrasekaran Adithan
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 75 - 81
  • [50] CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
    Sirachainan, Ekaphop
    Jaruhathai, Sureerat
    Trachu, Narumol
    Panvichian, Ravat
    Sirisinha, Thitiya
    Ativitavas, Touch
    Ratanatharathorn, Vorachai
    Chamnanphon, Montri
    Sukasem, Chonlaphat
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 149 - 153
12345